Company intelligence / Profile preview

Toksöz Group

Istanbul, Istanbul, Turkey

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Through its subsidiary Arven, Toksöz Group achieved the first Turkish-patented dry-powder inhaler (Arvohaler®) and developed Turkey’s first licensed biosimilar product, with a commercial-scale biopharmaceutical manufacturing facility. Focus areas include oncology, autoimmune, and respiratory.

Therapeutic areas: OncologyImmunologyPulmonology
Modalities: BiosimilarBiologicInhaler deviceSmall moleculeHormone
Industry: Biotech

Beyond the preview

Go deeper on Toksöz Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toksöz Group.

Explore the full profile